Teva licenses Polpharma biosimilar to ocrelizumab for global commercialization

6 min read

Teva Pharmaceuticals International GmbH and Polpharma Biologics International AG signed a global licensing agreement giving Teva exclusive commercialization rights for Polpharma's proposed biosimilar to ocrelizumab, pending regulatory approval. Polpharma will retain responsibility for development and manufacturing, while Teva will submit regulatory dossiers and commercialize both intravenous and subcutaneous formulations in the United States, Europe, Brazil, Canada, Australia, New Zealand, Israel and Turkey. The agreement supports Teva's biosimilars strategy and could broaden patient access to ocrelizumab treatment options if regulators approve the candidate.

Teva will commercialize Polpharma's ocrelizumab biosimilar upon approval.